Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Companyâ¿¿s segments are GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and ra... GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Companyâ¿¿s segments are GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and womenâ¿¿s health and somatic oncology diagnostic testing and screening products. Show more
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual...
New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today...
Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (Nasdaq: WGS), a leader in delivering improved health...
Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx industry leading dataset from 46% non-white...
Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical utility GeneDx (Nasdaq: WGS), a leader in delivering...
Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77% year-over-year growth of exome and genome test...
Findings published today in JAMA (Journal of the American Medical Association) reveal limitations of current screening methods and showcase the promise of advanced genomic technology to deliver...
Data to be presented at the International Conference on Newborn Sequencing (ICoNS) highlighting lessons learned from the GUARDIAN and Early Check newborn sequencing studies showcasing GeneDx’s...
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2024 before the market...
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of September 23, 2024, the compensation committee of GeneDx’s...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 5.37 | 7.60300155741 | 70.63 | 82.8 | 68.01 | 546185 | 76.23741816 | CS |
| 4 | -7.6 | -9.09090909091 | 83.6 | 89.1099 | 66 | 664115 | 76.32054664 | CS |
| 12 | 45.94 | 152.827677977 | 30.06 | 89.1099 | 28.86 | 595535 | 61.63667524 | CS |
| 26 | 54.81 | 258.659745163 | 21.19 | 89.1099 | 19.54 | 498280 | 47.76962593 | CS |
| 52 | 74.49 | 4933.11258278 | 1.51 | 89.1099 | 1.41 | 438036 | 32.2073035 | CS |
| 156 | 65.077 | 595.779547743 | 10.923 | 89.1099 | 1.16 | 962086 | 17.12727618 | CS |
| 260 | 65.077 | 595.779547743 | 10.923 | 89.1099 | 1.16 | 962086 | 17.12727618 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
